On November 25, 2024, iBio announced the appointment of David Arkowitz and António Parada as independent directors, enhancing its board with expertise in finance and antibody discovery. This move aligns with iBio's vision to advance its pipeline of therapeutic antibodies for cardiometabolic diseases and oncology.The appointments were part of the outcomes from the Annual Meeting held on November 21, 2024, where stockholders voted on three proposals. All nominees for Class I directors were elected, and Grassi & Co. was ratified as the independent accounting firm. Additionally, the compensation of named executive officers was approved on a non-binding basis.These strategic board additions are expected to support iBio's growth and development in the biotech sector, leveraging advanced biological techniques and machine learning in drug discovery.

On November 25, 2024, iBio announced the appointment of David Arkowitz and António Parada as independent directors, enhancing its board with expertise in finance and antibody discovery. This move aligns with iBio's vision to advance its pipeline of therapeutic antibodies for cardiometabolic diseases and oncology.The appointments were part of the outcomes from the Annual Meeting held on November 21, 2024, where stockholders voted on three proposals. All nominees for Class I directors were elected, and Grassi & Co. was ratified as the independent accounting firm. Additionally, the compensation of named executive officers was approved on a non-binding basis.These strategic board additions are expected to support iBio's growth and development in the biotech sector, leveraging advanced biological techniques and machine learning in drug discovery.